-
Venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia
Niemann, C. U., Levin, M.-D., Dubois, J., Kersting, S., Enggaard, L., Veldhuis, G. J., Mous, R., Mellink, C. H. M., Dobber, J. A., Poulsen, C. B., Frederiksen, H., Janssens, A., Schjødt, I., Dompeling, E. C., Ranti, J., Mattsson, M., Bellido, M., Tran, H. T. T., Nasserinejad, K. & Kater, A. P., 25 Feb 2021, In: Blood. 137, 8, p. 1117-1120 4 p.Research output: Contribution to journal › Comment/Letter to the editor* › Academic
-
Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: A multi-center study: A multi-center study
ERIC, the European Research Initiative on CLL, 1 Jan 2021, In: Haematologica. 105, 5Research output: Contribution to journal › Article* › Academic › peer-review
-
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
Kater, A. P., Wu, J. Q., Kipps, T., Eichhorst, B., Hillmen, P., D'Rozario, J., Assouline, S., Owen, C., Robak, T., de la Serna, J., Jaeger, U., Cartron, G., Montillo, M., Dubois, J., Eldering, E., Mellink, C., van der Kevie-Kersemaekers, A.-M., Kim, S. Y., Chyla, B. & Punnoose, E. & 8 others, , 1 Dec 2020, In: Journal of clinical oncology. 38, 34, p. 4042-4054 13 p.Research output: Contribution to journal › Article* › Academic › peer-review
- All publications
